Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen

Braal, C. Louwrens; Hussaarts, Koen G A M; Seuren, L.; Oomen-deHoop, E.; Bruijn, Peter de; Buck, Stefan A.J.; Bos, Monique E.M.M.; Thijs-Visser, M.F.; Zuetenhorst, Hanneke; Stein, Daniëlle Mathijssen‐van; Vastbinder, Mijntje B; Leeuwen, Roelof W F van; Gelder, Teun van; Koolen, Stijn L.W.; Jager, Agnes; Mathijssen, Ron H.J.

doi:10.1007/s10549-020-05979-7

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inter-individual variability in response to tamoxifen is high and many factors play roles in this phenomenon such as gender, age, obesity comorbidity, liver and renal function, pregnancy, drug-drug interactions and genetic polymorphisms in CYP2D6 metabolizing enzyme. [25][26][27][28][29][30][31] The DNA fragments obtained in the present study after application of PCR-RFLP technique on CYP2D6*4 (rs3892097; 1846 G>A) single nucleotide polymorphism (SNP) 32 , gave a pattern in electrophoresis similar to that in other studies on CYP2D6*4. [33][34][35] The distribution of CYP2D6*4 genotypes among the Egyptian patients in the present study was as follows: GG = 67 (65%), GA= 24 (23.3 %), and AA= 12 (11.7 %) and this distribution was deviated from Hardy Weinberg Equilibrium (HWE).…”

Section: Discussionsupporting

confidence: 66%

Prevalence of Cyp2d6*4 and Its Possible Relation to Therapeutic Outcomes of Adjuvant Tamoxifen Therapy in Egyptian Premenopausal Women With Breast Cancer

Hareedy

Taha²,

Ibrahim³

et al. 2022

Bulletin of Pharmaceutical Sciences. Assiut

View full text Add to dashboard Cite

Background: Although tamoxifen is a main adjuvant therapy in estrogen positive breast cancer especially in premenopausal women, reliance on genetic polymorphisms of its CYP2D6 metabolizing enzyme and/or therapeutic drug monitoring of its active metabolite, endoxifen to determine tamoxifen-therapeutic outcomes is debatable. Objective: The goal of the study was to investigate the prevalence of CYP2D6*4 and possible association between its nonfunctional allele (A) and both tamoxifen-induced adverse effects and cancer relapse in premenopausal breast cancer patients. Method:Polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) analysis was applied for detection of CYP2D6*4 (1846 G>A) genotypes. Results:Genotyping analysis of CYP2D6*4 showed a minimal allele frequency of 23%. Increased endometrial thickness in mm was significantly correlated with CYP2D6*4 GA and AA genotypes in comparison with GG genotypes (P< 0.01). No other relations were found between CYP2D6*4 alleles and other tamoxifen adverse effects (P > 0.9) or cancer relapse (P= 0.7). Conclusion: The prevalence of CYP2D6*4 polymorphism in Egyptian premenopausal females with breast cancer who are given tamoxifen is similar to that in Caucasians. The nonfunctional allele (A-allele) of CYP2D6*4 showed a significant association with increased endometrial thickness possibly related to tamoxifen, but no association with other drug adverse effects or cancer relapse.

show abstract